BioCatalyst

ENGN — enGene Therapeutics Inc. catalysts

1 verified catalyst event(s) for enGene Therapeutics Inc. (ticker ENGN). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-06-30 — LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Tr · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-06-30
in 8d
ESTIMATED
 READOUT
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incom
Phase 1/2 · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
 ENGN enGene Therapeutics Inc. EG-70 (phase 1), EG-70 (phase 2) Master ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.